Life Science

A potent, selective, brain permeable inhibitor of GSK3&alpha and GSK3&beta (Kis = 6.9 and 31 nM, respectively) shows good bioavailability after oral administration in vivo, inhibiting hippocampal tau phosphorylation and reversing cognitive

A potent, selective, brain permeable inhibitor of GSK3&alpha and GSK3&beta (Kis = 6.9 and 31 nM, respectively) shows good bioavailability after oral administration in vivo, inhibiting hippocampal tau phosphorylation and reversing cognitive

A potent, selective, brain permeable inhibitor of GSK3&alpha and GSK3&beta (Kis = 6.9 and 31 nM, respectively) shows good bioavailability after oral administration in vivo, inhibiting hippocampal tau phosphorylation and reversing cognitive

An orally bioavailable prodrug of AZD 1152-HQPA, a selective inhibitor of Aurora kinase B (IC₅₀ = 0.36 nM).

An orally bioavailable prodrug of AZD 1152-HQPA, a selective inhibitor of Aurora kinase B (IC₅₀ = 0.36 nM).

An orally bioavailable prodrug of AZD 1152-HQPA, a selective inhibitor of Aurora kinase B (IC₅₀ = 0.36 nM).

An orally bioavailable prodrug of AZD 1152-HQPA, a selective inhibitor of Aurora kinase B (IC₅₀ = 0.36 nM).

A potent, selective, and orally available inhibitor of Pim kinase (IC₅₀s = 0.4, 5.

A potent, selective, and orally available inhibitor of Pim kinase (IC₅₀s = 0.4, 5.

A potent, selective, and orally available inhibitor of Pim kinase (IC₅₀s = 0.4, 5.

A potent, selective, and orally available inhibitor of Pim kinase (IC₅₀s = 0.4, 5.

A PARP inhibitor (IC₅₀ = 5 nM) with low affinity for the P-glycoprotein drug efflux transporter induces a loss of p53 binding protein 1 expression in mice with KB1P tumors at 100 mg/kg.